[1] 陈圆生,李黎,崔富强,等.中国丙型肝炎血清流行病学研究.中华流行病学杂志,2011,32:888-891.
[2] Rao H,Wei L,Lopez-Talavera JC,eta1.Distribution and clinical Correlates of viral and host genotypesin Chinese patients with Chronic hepatitis C virus infection.JGastroenterol Hepatol,2014,29:545-553.
[3] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015更新版).中华肝脏病杂志,2015,12:906-923.
[4] Adhal N,Everson G,Calleja JL,et a1.Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis andportal hypertension with and without decompensation:early virologic responseand safety.J Hepatol,2014,60:S28.
[5] 肖宏.陶慧峰.等. 聚乙二醇干扰素治疗普通干扰素治疗失败的慢性丙型肝炎疗效分析.肝脏,2011,16:393-394.
[6] Eumpeall Association for Study of Livet EASL recommendations on treatmem of hepatitis C2015.J H Hepato,2015,63:199-236.
[7] European Association for Study of Liver.EASL clinical practice Guidelines:management of hepatitis C virus infection.J Hepatol,2014,60:392-420. |
